title: Galanthamine.
abstract: Galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of Alzheimer's disease. Galanthamine is selective for acetylcholinesterase versus butyrylcholinesterase; however, the drug produces greater enzyme inhibition in human erythrocytes than in human brain tissue. Galanthamine attenuates drug-and lesion-induced cognitive deficits in animal models of learning and memory. Preliminary results in patients with Alzheimer's disease have reported galanthamine to be associated with a reduction in cognitive deterioration on some neuropsychiatric rating scales. Nausea and vomiting are the most commonly reported adverse effects; liver toxicity has not been reported to date.
authors.affiliation: Adis International Limited, Auckland, New Zealand.
authors.forename: B
authors.initials: B
authors.lastname: Fulton
authors.forename: P
authors.initials: P
authors.lastname: Benfield
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D002986:Clinical Trials as Topic; D005702:Galantamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans
chemical_list: D002800:Cholinesterase Inhibitors; D005702:Galantamine